Figure S1 from Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor

Authors:

Abstract
(Ai) Box-plot shows the association of copy number of S100A4 gene to Gleason Score of prostate tumors in CaP patients. The graph was generated from the analysis of TCGA clinical data using Oncomine platform. (Aii) Image shows the detection of S100A4 protein in human serum as assessed by immune-Slot blot analyses. The immunoblot data shown here is a representative of experiments conducted three independent times. (Bi) The gel image shows the cloning of s100A4 in pET28a vector using NdeI and Xho I site. (Bii) Immunoblot image shows the detection of S100A4 for different elution fractions of S100A4 protein overexpressed in BL21DE3. (C) Histogram shows the effect of mab6B12 therapy on the rate of proliferation of human CaP cells as assessed by 3[H]thymidine uptake assay. (D) Graph shows the Osterix expression in Bone-mets in CaP patients from Met-CaP Provisional Project 2019 Clinical study as analyzed by cBioportal platform. (E) Heat map shows the gene expression profile of CD4+ T cells Co-cultured with TRAMP-C2 cells in presence and absence of S100A4 protein and mab6B12 antibody.